drugset / Trial / NCT05032690

Evaluation of the Relative Bioavailability of Bosutinib Capsules Under Fed Condition and Estimation of Food Effect on Orally Administered Bosutinib Capsule

NCT05032690

Phase 1 Completed 32 enrolled Pfizer
RandomizedCrossoverOpen-labelBasic science

Summary

This study is intended to estimate the bioavailability of a single 100 mg bosutinib capsules relative to four 25 mg capsules under fed condition in adult healthy participants and to estimate the effect of a high-fat, high-calorie meal on the bioavailability of a single 100 mg capsule of bosutinib relative to fasted condition in adults healthy participants. The comparisons will be performed using the pharmacokinetic parameters that define the rate and extend of absorption (Cmax, AUC). Statistical analyses will be performed after the administration of a single 100 mg dose under fed condition as the Reference treatment and the four 25 mg capsules as the Test treatment for the first comparison, and after administration of a single 100 mg dose under fasted condition as the Reference treatment and the 100 mg capsule under fed condition as the Test treatment for the second comparison.

Timeline

Start
2022-01-19
Primary completion
2022-06-25
Completion
2022-06-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Bosutinib Small molecule 100 mg Oral

Indications

No indication recorded.